Gene: MARS2
Official Full Name: methionyl-tRNA synthetase 2, mitochondrialprovided by HGNC
Gene Summary: This gene produces a mitochondrial methionyl-tRNA synthetase protein that is encoded by the nuclear genome and imported to the mitochondrion. This protein likely functions as a monomer and is predicted to localize to the mitochondrial matrix. Mutations in this gene are associated with the autosomal recessive neurodegenerative disease spastic ataxia-3 (SPAX3). [provided by RefSeq, Apr 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO22474 | MARS2 Knockout cell line (HeLa) | Human | MARS2 | 1:3~1:6 | Negative | Online Inquiry |
KO22475 | MARS2 Knockout cell line (HCT 116) | Human | MARS2 | 1:2~1:4 | Negative | Online Inquiry |
KO22476 | MARS2 Knockout cell line (HEK293) | Human | MARS2 | 1:3~1:6 | Negative | Online Inquiry |
MARS2 Gene Knockout Cell Lines are genetically engineered cell lines designed specifically for the targeted deletion of the MARS2 gene. This gene plays a crucial role in mitochondrial function and aminoacyl-tRNA biosynthesis; thus, its knockout provides invaluable insights into cellular metabolism, mitochondrial biology, and the underlying mechanisms of various genetic diseases. These cell lines serve as a powerful tool for researchers aiming to dissect the functional role of MARS2 in physiological and pathological contexts.
The primary mechanism of action of MARS2 Gene Knockout Cell Lines involves the use of CRISPR/Cas9 technology to induce double-strand breaks in the genomic DNA at specific sites within the MARS2 gene, leading to non-homologous end joining repair that results in gene disruption. This genetic alteration enables the analysis of the consequences of MARS2 deficiency on cell viability, proliferation, and energy metabolism, thereby providing a platform for in-depth exploration of disease models such as mitochondrial myopathies and other metabolic disorders.
Scientifically, the creation and utilization of MARS2 Gene Knockout Cell Lines are significant not only for advancing our understanding of mitochondrial dysfunction but also for drug discovery and testing. These cell lines can facilitate the screening of potential therapeutic agents aimed at restoring mitochondrial function or mitigating the effects of MARS2 deficiency, thereby promoting translational research in regenerative medicine and gene therapy.
Compared to traditional gene knockdown methods like siRNA, which often provide transient effects, our MARS2 Gene Knockout Cell Lines offer a stable and permanent genetic alteration, ensuring consistent results over prolonged experimental periods. This stable knockout allows for better reproducibility and reliability in experimental designs, making it an unmatched choice in the research landscape.
For researchers, clinicians, and biotechnology companies, MARS2 Gene Knockout Cell Lines represent a critical advancement in the toolkit for mitochondrial research, enhancing the ability to investigate disease mechanisms and develop novel treatments. Our company, with a strong foundation in genetic engineering and cellular technology, is committed to providing high-quality biological products that empower the scientific community in their quest for innovation.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.